<DOC>
	<DOCNO>NCT01962779</DOCNO>
	<brief_summary>Our preliminary data show cognitively-normal elderly , Sleep Disordered Breathing ( SDB ) associate increase cerebrospinal fluid ( CSF ) phosphorylated-Tau ( P-Tau ) total-Tau ( T-Tau ) , decrease medial temporal lobe glucose uptake ( FDG-PET ) volume ( MRI ) progressive memory decline , show useful predict future dementia old adult . These finding raise question whether Alzheimer 's disease ( AD ) tissue damage cause SDB elderly , alternatively , SDB act risk factor AD neurodegeneration . In proposed study , investigate mechanistic hypothesis cognitively normal elderly examine longitudinal association SDB cognitive decline , novel MR neuroimaging CSF biomarkers neurodegeneration ; secondary goal launch pilot treatment study aid interpret mechanistic hypothesis examine effect nasal continuous positive airway pressure ( CPAP ) cognitive decline neurodegeneration .</brief_summary>
	<brief_title>Sleep , Aging Risk Alzheimer 's Disease</brief_title>
	<detailed_description>Sleep disorder breathing ( SDB ) common disorder estimate prevalence elderly range 30-80 % . The relevance high frequency late life emerging , recent evidence suggest SDB may associate development mild cognitive impairment dementia . Alzheimer 's disease ( AD ) common form dementia affect nearly 45 % population old 85 . Hippocampal atrophy glucose hypometabolism , well change cerebrospinal fluid ( CSF ) level amyloid beta-42 ( AÎ²42 ) , phosphorylated-tau ( P-Tau ) total-tau ( T-Tau ) , show useful predict future decline cognitively normal old adult , suggest AD pathology detectable prior cognitive impairment at-risk subject . This `` presymptomatic phase '' , tissue damage minimal whose detection precede clinical symptom , ideal stage risk factor analysis intervention trial . Our preliminary data show , first time cognitively-normal elderly , severity SDB ( measure respiratory event 4 % desaturation , Apnea Hypopnea Index 4 % [ AHI4 % ] ) associate increase CSF P-Tau T-Tau , decrease glucose uptake ( measure FDG-PET ) medial temporal lobe , reduce hippocampal volume , longitudinal memory decline . These finding raise question whether AD tissue damage cause SDB elderly , alternatively , SDB act risk factor neurodegeneration . The propose parent grant project conduct NYU Center Brain Health ( CBH ) , 5-year NIH-funded longitudinal study 180 normal elderly ( 50-95 year ) , undergo complete baseline 24 month follow-up evaluation . The exams include MR imaging : structural cerebral blood flow ( CBF ) use novel NYU arterial spin labeling ( ASL ) protocol regional brain vasoreactivity estimate CO2 breathing ( VR-CO2 ) ; well plasma CSF biomarkers . The present ancillary proposal , perform collaboration NYU 's Sleep Disorders Center , investigate : 1 ) SDB longitudinal predictor change memory , level P-tau T-Tau , hippocampal atrophy , blunt VR-CO2 response ( effect SDB observe cross-section pilot work ) ; 2 ) SDB related phenomenon normal elderly susceptible intervention nasal continuous positive airway pressure ( CPAP ) moderate-to-severe SDB subject . This study potential identify : 1 ) highly prevalent AD-related mechanism SDB contribute cognitive decline ; 2 ) alternative hypothesis , presence biomarker feature AD risk factor SDB ; 3 ) treatment SDB CPAP improve cognition AD-related pathway elderly .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<criteria>Male female subject normal cognition &gt; 50 year age enrol . Younger subject include risk cognitive impairment low . Moreover , select agerange minimize possibility include earlyonset genetic form neurodegenerative disease Alzheimer 's disease Frontotemporal Dementia . Normal subject within normal limit neurological psychiatric examination . All subject enrol Clinical Dementia Rating = 0 Global Deterioration Scale &lt; 3 . All subject minimum 12 year education.The education restriction reduce performance variance cognitive test measure improve sensitivity detect pathology disease progression use robust norm available NYU School Medicine . All subject inform family member life partner interview confirm reliability subject interview . All subject agree MRI imaging , lumbar puncture , apolipoprotein E ( ApoE ) genotyping DNA banking Diagnosis brain disease MRI evidence brain damage include significant trauma , hydrocephalus , seizure , mental retardation serious neurological disorder ( e.g . Parkinson 's disease movement disorder ) . Persons silent cortical infarct exclude . Subcortical infarct white matter lesion exclusion . History brain tumor . Any radiation chemotherapy anywhere body past 3years . Significant history alcoholism drug abuse . History psychiatric illness ( e.g. , schizophrenia , mania , PTSD , life long history major depression ) . Hamilton Depression Scale &gt; 16 history life long depressive episode . Otherwise exclude . Evidence clinically relevant uncontrolled cardiac , pulmonary , hypothyroid hematological condition . Insulin dependent diabetes and/or history treat hypertension exclusion . Normal subject current level HbA1c &gt; 5.9 % diabetic &gt; 7.0 % ( American Diabetes Association , 2010 ) and/or current blood pressure level &gt; 140/90 mm Hg ( JNC Prevention , Detection , Evaluation Treatment High Blood Pressure , 2003 ) advise seek referral . Physical impairment severity adversely affect validity psychological testing . Hostility refusal cooperate . Any prosthetic device ( e.g. , pacemaker surgical clip ) constitute hazard MRI imaging . History firstdegree family member early onset ( age 65 ) dementia . Medications adversely affect cognition result exclusion . The excluded medication include : Antidepressants anticholinergic property . Regular use narcotic analgesic ( &gt; 2 dos per week ) . Use neuroleptic anticholinergic property . Other medication central nervous system anticholinergic activity . Use AntiParkinsonian medication . At baseline individual take physician order offlabel memory cognitive enhancing medication ( e.g . cholinesterase inhibitor memantine ) exclude . At followup medication allow . Also exclude baseline individual take physician order , offlabel memory enhancement . Individuals take counter memory enhance protect medication ( e.g . ginkgo biloba , vitamin ) exclude . Patients significant physical change ( e.g . amputation loss sensory input ) may affect MRI blood flow measure .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sleep Disordered Breathing</keyword>
	<keyword>Cognitively normal elderly</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Prevention</keyword>
	<keyword>Continuous positive airway pressure ( CPAP )</keyword>
</DOC>